Long-term evaluation of neurological outcomes in chemotherapy-associated posterior reversible encephalopathy (PRES) syndrome in children
PRES may complicate the oncological treatment in children. Hypertension is a leading risk factor for PRES, while it should be kept in mind that the blood pressure may be normal in chemotherapy-induced PRES cases. PRES should be included in the differential diagnosis of all patients receiving chemotherapy and presenting with acute neurological symptoms.
Authors
- Beril Dilber (ORCID: https://orcid.org/0000-0002-7633-0060)
- Erol Erduran (ORCID: https://orcid.org/0000-0002-8552-4596)
- Ayşenur Bahadır (ORCID: https://orcid.org/0000-0001-9226-369X)
- İlker Eyüboğlu (ORCID: https://orcid.org/0000-0002-7732-1289)
- Gökçe Pınar Reis İskenderoğlu
Institutions
- Karadeniz Technical University (TR)
Publication Details
- Journal
- Klinische Pädiatrie
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1055/a-2468-3799
- Citations
- 1
- Primary Topic
- Neurological Complications and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 0.39